Although high-density lipoprotein cholesterol has been deemed the “good cholesterol,” this label may be misleading and outdated given that there is little evidence to support a causal relationship with CVD risk reduction.
Researchers evaluated how feasible, safe, and effective evolocumab is at lowering low-density lipoprotein cholesterol when initiated in patients hospitalized with acute coronary syndrome.
The advisory from the American Heart Association aggregates the research performed thus far on the use of omega-3 fatty acids in hypertriglyceridemia and recommends a dose of 4 g/d to observe a therapeutic effect.
Sandoz announced a voluntary recall of certain lots of Losartan Potassium and Ezetimibe prescription bottles due to not meeting federal standards for child-resistant packaging as required by the Poison Prevention Packaging Act.
Lomitapide reduced low-density lipoprotein cholesterol in patients with homozygous familial hypercholesterolemia, with some patients reaching recommended targets.
A significant number of overweight and obese young people who are classified as nonhypertensive by the European Society of Hypertension criteria have high blood pressure and increased cardiovascular risk, according to newer American Academy of Pediatrics guidelines.
Fixed-dose bempedoic acid with ezetimibe lowered LDL-C vs placebo when added to maximally tolerated statin therapy in patients with high CVD risk and hypercholesterolemia.
